Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.
Sales
0.63KRW trillion
2019
0.66KRW trillion
2020
0.8KRW trillion
2021
  • 1961 Obtained the drug manufacturing permit
  • 1984 Established Pharmaceuticals
    business division
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2017 Merged with
    LG Life Sciences
  • 2019 Established the Global Innovation Center in Boston, US
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in ChinaSucceeded in phase II clinical trial of the new gout drug in the US
Division
Primary Care (PC) Primary Care (PC)
Special Care (SC) Special Care (SC)
Aesthetic Aesthetic
LG Chem Life Science Pipeline

As of November 2022

  • Aesthetic
  • Cell Therapy
  • Diabetes & Metabolism
  • Oncology & Immunology
  • Vaccine
  1. Preclinical (11)
    • LR20022
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Diabetes
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19131
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication NASH
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19020
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Obesity
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19025
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Osteoarthritis
      Modality Cell therapy
      Target Undisclosed
      Partner Medipost
    • LR19023
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR22011
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR20009
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19128
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner Avactar Life sciences

      Affimer® Technology

    • LR19155
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner -
    • LR20008
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication HA filler
      Modality HA
      Target HA
      Partner -
    • LR20062
      해당 프로젝트 팝업
      Molecule aP vaccine
      Stage Preclinical
      Indication aP vaccine
      Modality Vaccine
      Target aP vaccine
      Partner -
  2. Phase I (9)
    • LR19129
      해당 프로젝트 팝업
      Molecule CUE-102
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target WT-1
      Partner Cue Biopharma
    • LR19127
      해당 프로젝트 팝업
      Molecule CUE-101
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication HNSCC
      Modality Biologics
      Target HPV
      Partner Cue Biopharma
    • LR19125
      해당 프로젝트 팝업
      Molecule PDC*Lung
      Stage Phase 1
      (by Partner)
      Location summary Europe
      Indication NSCLC
      Modality Cell therapy
      Target Cancer vaccine
      Partner PDC*line Pharma
    • LR20011
      해당 프로젝트 팝업
      Molecule GEN-001
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Solid tumor
      Modality Microbiome
      Target Microbiome
      Partner Genome & Company
    • LR21004
      해당 프로젝트 팝업
      Molecule BLR21004
      Stage Phase 1
      (by Partner)
      Location summary Australia
      Indication Osteoarthritis
      Modality Gene therapy
      Target Nkx3.2/AAV
      Partner ICM
    • LR19021
      해당 프로젝트 팝업
      Molecule LB54640
      Stage Phase 1
      Location summary USA
      Indication Genetic Obesity
      Modality NCE
      Target MC4R
      Partner -
    • LR20056
      해당 프로젝트 팝업
      Molecule LG303174
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target VAP-1
      Partner TransThera
    • LR19123
      해당 프로젝트 팝업
      Molecule LC542019
      Stage Phase 1
      Location summary USA
      Indication Diabetes
      Modality NCE
      Target GPR120
      Partner -
    • LR19018
      해당 프로젝트 팝업
      Molecule LG203003
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target DGAT-2
      Partner -
  3. Phase II (3)
    • LR19114
      해당 프로젝트 팝업
      Molecule 6 in 1 Vaccine
      Stage Phase 2
      Indication 6 in 1 Vaccine
      Modality Vaccine
      Target 6 in 1 Vaccine
      Partner -

      Diphtheriae (D), Bordetella pertussis (wP),

      Clostridium tetani (T), Hepatitis B (HepB)

      Haemophilus influenzae type b(Hib)

      Vaccine-Associated Paralytic Poliomyelitis(IPV)

    • LR19019
      해당 프로젝트 팝업
      Molecule Zectivimod
      Synonyms:LC510255
      Stage Phase 2
      Location summary Republic of Korea
      Partner: China
      Indication Atopic dermatitis
      Modality NCE
      Target S1P1
      Partner TransThera
      (License-out)

      License-out, China

    • LR19024
      해당 프로젝트 팝업
      Molecule LG34053
      Stage Phase 1b/2
      Location summary Republic of Korea
      Indication Osteoarthritis
      Modality NCE
      Target Undisclosed
      Partner -
  4. Phase III (4)
  5. NDA (0)
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE